Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;38 Suppl 1(Suppl 1):S4-13.
doi: 10.1016/j.jsat.2010.01.011.

The first decade of the National Drug Abuse Treatment Clinical Trials Network: bridging the gap between research and practice to improve drug abuse treatment

Betty Tai  1 , Michele M Straus, David Liu, Steven Sparenborg, Ron Jackson, Dennis McCarty
Affiliations

The first decade of the National Drug Abuse Treatment Clinical Trials Network: bridging the gap between research and practice to improve drug abuse treatment

Betty Tai et al. J Subst Abuse Treat. 2010 Jun.

Abstract

The National Institute on Drug Abuse established the National Drug Abuse Treatment Clinical Trials Network (CTN) in 1999 to improve the quality of addiction treatment using science as the vehicle. The network brings providers from community-based drug abuse treatment programs and scientists from university-based research centers together in an alliance that fosters bidirectional communication and collaboration. Collaboration enhanced the relevance of research to practice and facilitated the development and implementation of evidence-based treatments in community practice settings. The CTN's 20 completed trials tested pharmacological, behavioral, and integrated treatment interventions for adolescents and adults; more than 11,000 individuals participated in the trials. This article reviews the rationale for the CTN, describes the translation of its guiding principles into research endeavors, and anticipates the future evolution of clinical research within the Network.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CTN governance structure (p5)
See this image and copyright information in PMC

References

    1. Albright L, Hamilton JA, Kellogg S, Kileen T, Petry NM, Rosenfield J, Shanahan A, Peters C, Skinstad AH, Stitzer ML. Promoting Awareness of Motivational Incentives. 2006. Addiction Tehcnology Transfer Center Network: http://www.attcnetwork.org/exlore/priorityareas/science/blendinginitiati...
    1. Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. American Journal on Addictions. 2004;13(Suppl 1):542–566. - PMC - PubMed
    1. Ball SA, Martino S, Nich C, Frankforter TL, Van Horn D, Crits-Christoph P, et al. Site matters: multisite randomized trial of motivational enhancement therapy in community drug abuse clinics. Journal of Consulting and Clinical Psychology. 2007;75(4):556–567. - PMC - PubMed
    1. Bickel WK, Amass L, Higgins ST, Badger GJ, Esch RA. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. Journal of Consulting and Clinical Psychology. 1997;65(5):803–810. - PubMed
    1. Brigham GS, Amass L, Winhusen T, Harrer JM, Pelt A. Using buprenorphine short-term taper to facilitate early treatment engagement. Journal of Substance Abuse Treatment. 2007;32(4):349–356. - PubMed

Publication types

MeSH terms